Robert Maki
#116,981
Most Influential Person Now
Researcher
Robert Maki's AcademicInfluence.com Rankings
Robert Makicomputer-science Degrees
Computer Science
#6331
World Rank
#6678
Historical Rank
Computational Linguistics
#1063
World Rank
#1077
Historical Rank
Machine Learning
#2017
World Rank
#2043
Historical Rank
Artificial Intelligence
#2269
World Rank
#2308
Historical Rank
Download Badge
Computer Science
Robert Maki's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Robert Maki Influential?
(Suggest an Edit or Addition)According to Wikipedia, Robert Maki is an American medical oncologist, Professor of Medicine at the Hospital of the University of Pennsylvania, He is a specialist in the management of and translational research regarding sarcoma, the group of connective tissue malignancies that include leiomyosarcoma, gastrointestinal stromal tumor , liposarcoma, angiosarcoma, Ewing sarcoma, desmoid tumor and many others.
Robert Maki's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. (2010) (3445)
- A framework for advancing our understanding of cancer-associated fibroblasts (2020) (1376)
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial (2009) (1246)
- NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. (2010) (1010)
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2013) (1006)
- Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. (2008) (942)
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (2011) (875)
- Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation (2005) (774)
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. (2017) (728)
- Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. (2010) (703)
- Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. (2008) (662)
- Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy (2010) (653)
- Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. (2002) (629)
- NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. (2007) (623)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. (2016) (572)
- Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 (1997) (560)
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial (2016) (559)
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas (2007) (522)
- Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. (2009) (510)
- Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) (2008) (478)
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. (2009) (443)
- Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. (2011) (415)
- A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites (2011) (411)
- A 14‐Year Retrospective Review of Angiosarcoma: Clinical Characteristics, Prognostic Factors, and Treatment Outcomes with Surgery and Chemotherapy (2005) (371)
- Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. (2003) (354)
- Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors (2008) (353)
- Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. (2010) (338)
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. (2007) (313)
- Advances in sarcoma genomics and new therapeutic targets (2011) (312)
- Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. (2004) (297)
- Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor (2007) (296)
- High prevalence of CIC fusion with double‐homeobox (DUX4) transcription factors in EWSR1‐negative undifferentiated small blue round cell sarcomas (2012) (292)
- R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. (2011) (287)
- Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. (2009) (285)
- Consistent MYC and FLT4 gene amplification in radiation‐induced angiosarcoma but not in other radiation‐associated atypical vascular lesions (2011) (278)
- The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas (2007) (276)
- ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours (2010) (255)
- Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature (2005) (254)
- Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. (2014) (252)
- Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. (2005) (246)
- Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors (2008) (242)
- Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans (2002) (241)
- KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. (2009) (237)
- Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis (2010) (231)
- Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses (2003) (230)
- Altered bone and mineral metabolism in patients receiving imatinib mesylate. (2006) (229)
- Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. (2003) (227)
- Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. (2009) (223)
- Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis (2012) (221)
- Sorafenib for Advanced and Refractory Desmoid Tumors (2018) (214)
- Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. (2007) (210)
- Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor (2007) (206)
- Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. (2009) (204)
- Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. (2010) (200)
- Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial (2010) (198)
- Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model (2017) (195)
- The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. (2020) (194)
- Chemotherapy Is Associated With Improved Survival in Adult Patients With Primary Extremity Synovial Sarcoma (2007) (192)
- Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. (2004) (192)
- Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site (2004) (191)
- Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. (2007) (188)
- NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. (2004) (188)
- Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors (2017) (187)
- Stress-induced proteins in immune response to cancer. (1991) (186)
- Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. (2005) (184)
- Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) (2010) (179)
- A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. (2008) (172)
- Advanced chondrosarcomas: role of chemotherapy and survival. (2012) (171)
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. (2013) (164)
- The Impact of Chemotherapy on the Survival of Patients With High-grade Primary Extremity Liposarcoma (2004) (159)
- Monogenic and polygenic determinants of sarcoma risk: an international genetic study. (2016) (157)
- Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). (2010) (157)
- Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. (2004) (156)
- Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma (2013) (156)
- Malignant peripheral nerve sheath tumors. (2014) (155)
- Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). (2011) (152)
- A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients (2008) (151)
- A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma (2013) (150)
- Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. (2012) (149)
- Patient-derived xenografts for individualized care in advanced sarcoma (2014) (148)
- Opportunities for improving the therapeutic ratio for patients with sarcoma. (2007) (146)
- Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins. (1990) (145)
- Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor (2007) (144)
- Evidence-based recommendations for local therapy for soft tissue sarcomas. (2007) (144)
- Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial (2013) (143)
- PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. (2016) (140)
- A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. (2012) (131)
- Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors (2007) (128)
- Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure (2009) (126)
- Extraskeletal myxoid chondrosarcoma (2008) (119)
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. (2019) (119)
- Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas (2012) (119)
- Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) (2005) (117)
- Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. (2012) (113)
- SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). (2004) (109)
- A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas (2005) (103)
- Pleomorphic Characteristics of a Germ-Line KIT Mutation in a Large Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and Dysphagia (2004) (103)
- Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. (2005) (101)
- Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. (2017) (101)
- Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma (2003) (100)
- Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2018) (98)
- Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. (2013) (96)
- Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. (2006) (94)
- Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. (2015) (94)
- The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial (2012) (93)
- Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium (2008) (93)
- Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas (2012) (91)
- The miR-17-92 Cluster and Its Target THBS1 Are Differentially Expressed in Angiosarcomas Dependent on MYC Amplification (2012) (91)
- Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial (2018) (90)
- Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. (2007) (88)
- Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance (2009) (86)
- New inhibitors of renin that contain novel phosphostatine Leu-Val replacements. (1990) (86)
- Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. (2011) (86)
- A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma (2007) (84)
- Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000 (2005) (84)
- Role of Interleukin 12 and Costimulators in T Cell Anergy In Vivo (1997) (81)
- A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials (2012) (81)
- Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor (2010) (79)
- Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. (2010) (79)
- Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. (2011) (78)
- IGF2 over‐expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting (2010) (78)
- Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy (2011) (77)
- Development and clinical application of an integrative genomic approach to personalized cancer therapy (2016) (76)
- Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033 (2017) (74)
- Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. (2010) (74)
- A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. (2008) (73)
- Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors (2007) (73)
- Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas (2020) (71)
- Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. (2010) (70)
- Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. (2015) (70)
- Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network (2020) (70)
- Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2020) (69)
- Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum. (2013) (69)
- Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review (2019) (66)
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. (2012) (64)
- Why Do Patients with Low-Grade Soft Tissue Sarcoma Die? (2008) (64)
- Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity (2002) (63)
- Advances in sarcoma genomics and new therapeutic targets (2011) (62)
- Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. (2015) (61)
- Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib (2012) (60)
- Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. (2019) (60)
- Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. (2015) (60)
- A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. (2002) (58)
- A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors (2008) (57)
- Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. (2018) (55)
- Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)† (2018) (55)
- Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials (2013) (55)
- Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. (2018) (53)
- Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. (2016) (53)
- Toward Better Soft Tissue Sarcoma Staging: Building on American Joint Committee on Cancer Staging Systems Versions 6 and 7 (2013) (50)
- Chemotherapy in clear cell sarcoma (2011) (49)
- Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. (2011) (48)
- ETV1 is a lineage-specific survival factor in GIST and cooperates with KIT in oncogenesis (2010) (47)
- Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. (2010) (46)
- Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft‐tissue sarcoma of the extremity (2007) (46)
- Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. (2017) (46)
- Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series (2013) (46)
- Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors (2006) (45)
- Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma (2015) (45)
- New Therapeutic Targets in Soft Tissue Sarcoma (2012) (43)
- EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases (2008) (42)
- Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas (2019) (42)
- Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. (2013) (42)
- GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. (2015) (41)
- Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma (2019) (39)
- International expert opinion on patient-tailored management of soft tissue sarcomas. (2014) (38)
- De Novo Osteogenic Sarcoma in Patients Older Than Forty: Benefit of Multimodality Therapy (2005) (38)
- Evaluation of the rate constant for the reaction OH+H2CO: Application of modeling and sensitivity analysis techniques for determination of the product branching ratio (1989) (38)
- Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy (2015) (36)
- Pediatric sarcomas occurring in adults (2008) (35)
- Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. (2017) (35)
- A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. (2012) (35)
- Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. (1997) (35)
- Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. (2011) (34)
- TERT promoter mutations in solitary fibrous tumour (2018) (34)
- Cascades of transcriptional induction during human lymphocyte activation. (2001) (34)
- Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. (2003) (34)
- Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). (2015) (34)
- Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor (2019) (33)
- Angiosarcomas and other sarcomas of endothelial origin. (2013) (33)
- Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060) (2007) (32)
- Pigmentary changes in a patient treated with imatinib. (2011) (32)
- Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. (2012) (31)
- Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma. (2017) (31)
- An IRAK1-PIN1 Signalling Axis Drives Intrinsic Tumour Resistance to Radiation Therapy (2018) (30)
- The enantio- and diastereoselective synthesis of the first phospho-statine derivative (1986) (30)
- Alterations of p53 and PIK3CA/AKT/mTOR Pathways in Angiosarcomas: A Pattern Distinct from Other Sarcomas with Complex Genomics (2012) (30)
- Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. (2015) (30)
- A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas (2006) (29)
- Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. (2013) (29)
- Lyman-.alpha. photometry: curve of growth determination, comparison to theoretical oscillator strength, and line absorption calculations at high temperature (1985) (29)
- Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. (2018) (29)
- Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. (2015) (29)
- Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma (2015) (29)
- Soft tissue sarcoma as a model disease to examine cancer immunotherapy. (2001) (29)
- Sarcomas with spindle cell morphology. (2009) (29)
- A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. (2012) (28)
- Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma (2018) (28)
- A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. (2017) (28)
- Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). (2010) (26)
- The Activity of Sunitinib against Gastrointestinal Stromal Tumor Seems to be Distinct from Its Antiangiogenic Effects (2006) (26)
- DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). (2006) (26)
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (26)
- Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. (2013) (25)
- A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). (2010) (25)
- Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy (2004) (24)
- Role of chemotherapy in patients with soft tissue sarcomas (2004) (23)
- First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies. (2019) (23)
- Mechanisms of sarcomagenesis. (2005) (23)
- A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. (2006) (22)
- Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060 (2008) (22)
- Effi cacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib ( GRID ) : an international , multicentre , randomised , placebo-controlled , phase 3 trial (2013) (22)
- Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network (2019) (22)
- Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS). (2013) (22)
- Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study (2019) (22)
- Primary Angiosarcoma of Bone: A Retrospective Analysis of 60 Patients From 2 Institutions (2014) (22)
- Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST) : Subgroup analysis of outcomes based on pretreatment characteristics (2013) (21)
- Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review. (2016) (21)
- SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. (2015) (20)
- Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site. (1990) (20)
- A context dependent role for Wnt signaling in tumorigenesis and stem cells (2008) (20)
- CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers (2012) (20)
- Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement. (1987) (19)
- Future directions for immunotherapeutic intervention against sarcomas (2006) (19)
- Benign Mesenchymal Stromal Cells in Human Sarcomas (2010) (19)
- Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. (2006) (18)
- Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial. (2014) (18)
- Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial (2008) (18)
- A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). (2015) (18)
- Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. (2012) (17)
- JNCCN NCCN Task Force Report : Optimal Management of Patients with Gastrointestinal Stromal Tumor ( GIST ) — Update of the NCCN Clinical Practice Guidelines (2007) (17)
- Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study. (2017) (17)
- A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas (2019) (17)
- Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma. (2012) (17)
- Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. (2013) (17)
- Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). (2011) (16)
- A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS). (2016) (16)
- Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications (2013) (15)
- Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma (2003) (15)
- Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. (2014) (15)
- Benign Soft Tissue Tumors (2013) (14)
- A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). (2006) (14)
- Cruciferous vegetables consumption and the risk of female lung cancer : a prospective study and a meta-analysis (14)
- Treatment of soft tissue sarcoma: a focus on earlier stages. (2017) (14)
- Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours (2019) (14)
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (14)
- Efficacy of sorafenib in patients with desmoid-type fibromatosis. (2016) (14)
- Novel HMGA2-YAP1 fusion gene in aggressive angiomyxoma (2019) (14)
- Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma (2018) (13)
- Alveolar Soft Part Sarcoma (2013) (13)
- Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma (2022) (13)
- Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST) (2005) (13)
- Desmoplastic Small Round Cell Tumor (2013) (13)
- 1480PDA phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival (2017) (13)
- Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS) (2019) (13)
- New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents (2012) (12)
- Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. (2011) (12)
- Recent advances in therapy for gastrointestinal stromal tumors (2007) (12)
- Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1 (2021) (12)
- Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies: Report of an expanded phase II trial. (2004) (12)
- A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. (2018) (11)
- Consumptive Coagulopathy in Angiosarcoma: A Recurrent Phenomenon? (2014) (11)
- Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab (2020) (11)
- Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival. (2011) (11)
- A Method to Summarize Toxicity in Cancer Randomized Clinical Trials (2018) (11)
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study (2018) (11)
- Targeting sarcoma tumor-initiating cells through differentiation therapy. (2017) (10)
- A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS). (2012) (10)
- A case of high-risk penile epithelioid hemangioendothelioma (2009) (10)
- A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. (2012) (10)
- Other targetable sarcomas. (2009) (10)
- Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer (2013) (10)
- Phase II study of the HSP 90-inhibitor BIIB 021 in gastrointestinal stromal tumors (2012) (10)
- Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule (2001) (10)
- Treatment of Adult Soft Tissue Sarcoma: Old Concepts, New Insights, and Potential for Drug Discovery (2012) (10)
- Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). (2018) (9)
- Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma (2020) (9)
- Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005. (2010) (9)
- Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs (2017) (9)
- Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. (2012) (9)
- Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. (2019) (9)
- Gastrointestinal Stromal Tumors (GIST) and Their Management. (2007) (9)
- Solitary Fibrous Tumor/Hemangiopericytoma (2013) (9)
- Soft Tissue Sarcoma of the Retroperitoneum (2017) (9)
- O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors (1996) (9)
- Immunity against soft-tissue sarcomas (2003) (8)
- Role of interleukin 12 and costimulators in T cell anergy in vivo (1997) (8)
- A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival. (2019) (8)
- A first-in-human, phase Ib combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma. (2012) (8)
- Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. (2004) (8)
- Management dilemmas due to a paratracheal follicular dendritic cell tumor. (2006) (8)
- Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. (1988) (8)
- Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. (2004) (8)
- Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival. (2011) (8)
- Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. (2009) (7)
- Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS). (2017) (7)
- Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis. (2015) (7)
- Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS). (2016) (7)
- Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings (2007) (7)
- Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis (2010) (7)
- A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). (2015) (6)
- Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS). (2016) (6)
- Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma (2021) (6)
- Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS) (2007) (6)
- Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin (2019) (6)
- Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation (2015) (6)
- EBV-Associated SmoothMuscle Neoplasms : Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases (2014) (6)
- Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update (2012) (6)
- Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. (2011) (6)
- 3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) (2015) (6)
- 369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) (2010) (6)
- Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers. (2012) (5)
- Novel osteoporosis mutation caused by the knock out of the hematopoietic transcription factor PU.1 in transgenic mice (1996) (5)
- Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. (2012) (5)
- Eribulin in soft-tissue sarcomas. (2011) (5)
- Psychological Distress of Internal Medicine Residents Rotating on a Hematology and Oncology Ward: An Exploratory Study of Patient Deaths, Personal Stress, and Attributed Meaning (2015) (5)
- Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options (2016) (5)
- Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. (2012) (5)
- A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST). (2011) (5)
- The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST) (2012) (5)
- Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST. (2013) (4)
- Introduction to Soft Tissue Sarcoma (2017) (4)
- A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results (2022) (4)
- 7505 ORAL Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas (2007) (4)
- Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic (2020) (4)
- A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. (2006) (4)
- Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. (2016) (4)
- The somatic mutational landscape in soft tissue sarcoma: Early results from TCGA data. (2015) (4)
- Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. (2022) (4)
- Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma (2022) (4)
- Undifferentiated Pleomorphic Sarcoma (UPS; Malignant Fibrous Histiocytoma: MFH) and Myxofibrosarcoma (2013) (4)
- Subtyping soft tissue sarcomas for treatment approaches (2012) (4)
- Soft Tissue Sarcoma of the Trunk and Extremities (2017) (4)
- When Benign Tumors Mimic Malignancies: A Case of Lymphangiomatosis Masquerading as Metastatic Disease (2013) (4)
- Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr). (2010) (3)
- 48 Phase I study of HSPPC-96 (oncophage®) vaccine in patients with completely resected pancreatic adenocarcinoma (2003) (3)
- Cutaneous metastasis of a perivascular epithelioid cell tumor. (2014) (3)
- ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy. (2021) (3)
- Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study (2022) (3)
- Targeted therapy in sarcoma: should we be lumpers or splitters? (2012) (3)
- 1497PEfficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: A retrospective analysis (2017) (3)
- 479 Impact of the DNA repair efficiency in the outcome of sarcoma patients treated with ET-743 (Yondelis) (2004) (3)
- Natural History: Importance of Size, Site, and Histopathology (2013) (3)
- DNA Copy Number Analysis in Gastrointestinal Stromal Tumors Using Gene Expression Microarrays (2008) (3)
- Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches (2016) (3)
- Impact of Intraoperative Molecular Imaging after Fluorescent-Guided Pulmonary Metastasectomy for Sarcoma. (2022) (3)
- An iterative synthesis of radiolabelled polyethylene glycol oligomers (1989) (3)
- Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients. (2016) (3)
- Stress and empathy among internal medicine trainees on an inpatient hematology-oncology ward. (2014) (3)
- Soft Tissue Sarcoma of the Head and Neck (2016) (3)
- 9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age (2009) (2)
- Definitive Local Therapy Is Associated with Improved Survival in Metastatic Soft Tissue Sarcomas (2021) (2)
- Faculty Opinions recommendation of Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. (2008) (2)
- A putative tumor suppressor role for Wnt-signaling in sarcomagenesis. (2006) (2)
- Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. (2012) (2)
- A model for multi-institutional, multidisciplinary sarcoma videoconferencing. (2013) (2)
- Association of Notch signaling pathway expression in liposarcomas with outcome, and targeting with gamma-secretase inhibitors. (2009) (2)
- Ewing sarcoma and related FET family translocation‐associated round cell tumors: A century of clinical and scientific progress (2022) (2)
- Regorafenib for the Treatment of Sarcoma (2022) (2)
- Cardiac toxicity in a phase II study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas (STS). (2004) (2)
- Fighting Cancer Through the Study of Sarcomas (2005) (2)
- Surgical Management of Sarcoma Metastatic to Liver. (2021) (2)
- Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study (2019) (2)
- Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. (2022) (2)
- Sarcomas of Soft Tissue (2014) (2)
- Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor (2013) (2)
- Systemic therapy in clear cell sarcoma. (2010) (2)
- Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028. (2017) (2)
- In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study. (2016) (2)
- 9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin (2009) (2)
- Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET (2008) (2)
- A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma. (2021) (2)
- GIST and Breast Cancer: 3 Case Reports and a Review of the Literature (2009) (2)
- Clear Cell Sarcoma/Melanoma of Soft Parts (2013) (2)
- MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas. (2022) (2)
- Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase 3 SAR-3007 study (2016) (2)
- Soft Tissue Sarcoma – Unusual Histologies and Sites (2017) (2)
- S100 and CD34 Expressing Mesenchymal Neoplasm With Rare PLEKHH2::ALK Fusion and Response to ALK Inhibition (2022) (2)
- The Enantio- and Diastereoselective Synthesis of the First Phosphostatine Derivative. (1986) (2)
- Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. (2011) (2)
- 3436 Efficacy and safety of trabectedin (T) or dacarbazine (D) for treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy (2015) (1)
- Modern Soft Tissue Pathology: MEDICAL ONCOLOGY OF SOFT TISSUE SARCOMAS (2010) (1)
- DNA repair efficiency as a model for personalized therapy with Trabectedin (2007) (1)
- An application of statistical process control measures for maintaining optimal quality from dry kiln operations (1991) (1)
- Subgroup analysis of leiomyosarcoma patients from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma (2017) (1)
- Correlation of KIT and PDGFRA mutation status with sunitinib activity in imatinib-resistant GIST (2006) (1)
- Bluish papule in a middle-aged man. (2005) (1)
- Extraskeletal Osteogenic Sarcoma (2013) (1)
- General Statement as to Efficacy of Surgery/Chemotherapy/Radiation Therapy (2013) (1)
- Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS). (2018) (1)
- Molecular Characterization of Pediatric Gastrointestinal (2008) (1)
- General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy (2016) (1)
- SELNET Clinical practice guidelines for bone sarcoma. (2022) (1)
- Demonstration of gender-specific variability in a pharmacokinetic (PK) analysis of the PERSIST-5 trial of adjuvant imatinib (IM) for patients with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence. (2013) (1)
- A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. (2022) (1)
- Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMS (2016) (1)
- 93 – Sarcomas of Soft Tissue* (2014) (1)
- Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT). (2015) (1)
- Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors (2009) (1)
- Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy. (2012) (1)
- Pharmacodynamic case study of sunitinib/SU11248 in a gastrointestinal stromal tumor patient: Evidence toward a mechanism of effect. (2006) (1)
- 1498PEfficacy and safety of trabectedin in an elderly patient subgroup (≥65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) from the Expanded Access Program (EAP) (2017) (1)
- Problems in Colon Cancer and a Child With Renal Lymphoma (2016) (1)
- A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma. (2015) (1)
- Sarcoma: The Merging of Science and Clinical Care. (2018) (1)
- Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST) (2010) (1)
- Sarcomas More Common in Children (2013) (1)
- Metastatic colon cancer to the ovaries in a Krukenberg-like pattern. (2005) (1)
- A framework for advancing our understanding of cancer-associated fibroblasts (2020) (1)
- tumors harboring KIT AY502-3ins mutation: an in vitro mutagenesis screen for drug-resistance (2010) (1)
- Utility of immune checkpoint inhibitors (ICI) in 3 patients (pts) with sarcomas of antigen presenting cells (follicular dendritic cell sarcoma [FDCS], histiocytic sarcoma [HS]). (2020) (1)
- Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). (2012) (1)
- Radiation-Induced Sarcomas (2013) (0)
- Postradiation cardiac sarcoma and other secondary cancers more than 25 years after chemotherapy and mantle-field radiation for Hodgkin's lymphoma (2015) (0)
- PS-2Phase (ph) 3 study of eribulin (ERI) vs dacarbazine (DTIC) in leiomyosarcoma (LMS) and liposarcoma (LPS) patients (pts) (2016) (0)
- Other Uterine Sarcomas (2013) (0)
- Radiation-Induced Sarcoma (2016) (0)
- Sustentacular Tumors of Lymph Tissue (2013) (0)
- Human Cancer Biology Benign Mesenchymal Stromal Cells in Human Sarcomas (2010) (0)
- cacy of Imatinib in Aggressive Fibromatosis: Results of a se II Multicenter Sarcoma Alliance for Research (2010) (0)
- Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D). (2018) (0)
- A Phase 0 Master Protocol Utilizing a Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Drug Combinations in Patients with Solid Tumors (2022) (0)
- Advanced soft-tissue sarcoma in patients over age 75: Patterns of care and survival. (2012) (0)
- CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply. (2007) (0)
- S3564 Use of EUS to Characterize a Rare Gastric Tumor with EWSR1-CREM Fusion (2022) (0)
- Clinical outcomes of systemic therapy for patients with desmoids. (2009) (0)
- APhase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors (2008) (0)
- Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma (2019) (0)
- Abstract CT216: A phase 0 master protocol utilizing a novel intratumoral microdosing approach for simultaneously evaluating multiple drugs and drug combinations in patients with solid tumors (2022) (0)
- β-catenin loss-of-function and its putative role as a tumor suppressor in sarcomagenesis (2006) (0)
- Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors. (2012) (0)
- Abstract C250: The pericyte as a novel stromal element and therapeutic target in sarcoma (2009) (0)
- Derives d'indole inhibant la biosynthese de leucotriene (1991) (0)
- The Influence of Older Age on Outcome in Soft Tissue Sarcoma of the Extremity (2005) (0)
- Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. (2023) (0)
- Fibrosarcoma and Its Variants (2013) (0)
- Association of Definitive Local Therapy with Survival in Patients with Metastatic Soft Tissue Sarcoma (2020) (0)
- Abstract 2155: High-plex spatial profiling analysis of multidrug CIVO microdose studies in cancer patients (2019) (0)
- 1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy (2015) (0)
- Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy. (2012) (0)
- A novel HMGA2-YAP1 fusion gene in a patient with aggressive angiomyxoma. (2019) (0)
- How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas. (2012) (0)
- Chromosome 9p21 Amplification in HNSCC Is Associated With Increased Mortality Following Adjuvant Radiation Therapy (2015) (0)
- RNA interference against cancer associated genes (2006) (0)
- Corrigendum to "SELNET clinical practice guidelines for bone sarcoma" Critical reviews in oncology/hematology, vol. 174 (2022), 1-10. (2022) (0)
- 364 A summary score to assess toxicity of small molecule oral kinase inhibitors (SMOKIs) in randomized clinical trials (RCTs) (2015) (0)
- Renin inhibitors containing a C-terminal heterocycle (1990) (0)
- Full Title: Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma Short Title: Predictive Algorithms for Personalized Drug Combinations (2018) (0)
- Uncommon/Unique Sites (2013) (0)
- Safety and efficacy of trabectedin when administered in the inpatient vs. outpatient setting in a subset analysis of a phase III randomized clinical trial. (2017) (0)
- The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy (2014) (0)
- Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors (2016) (0)
- Uterine Sarcomas in the Elderly (2013) (0)
- Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis) (2013) (0)
- Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials. (2023) (0)
- Mostly Benign/Rarely Metastasizing (2016) (0)
- Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D). (2019) (0)
- Direct visualization of circulating sarcoma cells by whole-blood fluorescence in situ hybridization. (2010) (0)
- Linking kinases to adverse events through kinase inhibitors. (2013) (0)
- Molecular profiling of liposarcoma subtypes (2005) (0)
- How Do I Treat Patients with Metastatic Soft Tissue Sarcoma (2012) (0)
- Modeling leiomyosarcoma in the mouse (2006) (0)
- Patient-derived xenografts effectively capture patient clinical responses to oncology therapy (2016) (0)
- Evaluation and Management of Sarcomas (2018) (0)
- Faculty Opinions recommendation of Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. (2007) (0)
- IS3. Gastric Cancer (2012) (0)
- Targeting HDM2 (Human MDM2) in Sarcomas (2012) (0)
- Abstract B40: Mouse clinical trials: integrating PDX models of sarcoma subtypes with genomics to replicate patient responses to cancer therapeutics (2016) (0)
- Mostly Benign/Rarely Metastasizing Soft Tissue Tumor (2013) (0)
- Lenalidomide and the expanding toolkit to manage Kaposi sarcoma. (2022) (0)
- An IRAK1–PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy (2019) (0)
- Flashback Foreword: Single-Agent Anti-Programmed Cell Death Protein 1 Therapy for Refractory Solid Tumors. (2023) (0)
- 1484PDA matching-adjusted indirect comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas (2017) (0)
- Structure‐Activity Relationships of N‐Hydroxyurea 5‐Lipoxygenase Inhibitors. (1997) (0)
- Psychological Distress of Internal Medicine Residents Rotating on a Hematology and Oncology Ward: An Exploratory Study of Patient Deaths, Personal Stress, and Attributed Meaning (2015) (0)
- Gastrointestinal Stromal Tumors (GISTs) (2013) (0)
- Sarcoma tumor size (T) staging: Are radiology or pathology measurements more appropriate? (2017) (0)
- Management of soft tissue sarcoma: Second edition (2016) (0)
- Comments regarding lung metastasis surgery for sarcoma. (2011) (0)
- Visualzing toxicity: A single score to summarize toxicity in randomized clinical trials. (2016) (0)
- Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas (2022) (0)
- Genome-wide analysis and characterization of an online sarcoma cohort. (2012) (0)
- The Rare Florid Osteomatous Jaw Lesion of Gardner Syndrome: A Case Report (2017) (0)
- Selected Benign Tumors (2016) (0)
- Introduction: the 2008 European society for medical oncology international symposium on sarcomas and gastrointestinal stromal tumors. (2009) (0)
- Development and clinical application of an integrative genomic approach to personalized cancer therapy (2016) (0)
- Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database (2021) (0)
- 1573PDPATIENT-DERIVED XENOGRAFTS ACCURATELY CAPTURE CLINICAL RESPONSES TO TREATMENT. (2014) (0)
- Lymphocytes and immune checkpoint biomarker expression in sarcomas (2018) (0)
- Multidisciplinary Management of Soft-Tissue Sarcomas (2002) (0)
- Brain Metastases(BM) in Patients (PTS) with Soft Tissue and Bone Sarcoma (Sarcoma): A Retrospective Study of 107 Pts (2012) (0)
- Abstract LB-62: Direct visualization of circulating sarcoma cells by whole-blood fluorescence in-situ hybridization (2010) (0)
- A comparison of three clinical factors as predictive markers for response to immunotherapy in non-small cell lung cancer. (2018) (0)
This paper list is powered by the following services:
Other Resources About Robert Maki
What Schools Are Affiliated With Robert Maki?
Robert Maki is affiliated with the following schools:
- University of California, Berkeley
- MD Anderson Cancer Center
- University of Michigan
- Icahn School of Medicine at Mount Sinai
- University of Toronto
- Massachusetts General Hospital
- Seoul National University
- Washington University in St. Louis
- Stanford University
- Oregon Health & Science University
- University of Utah
- University of Pennsylvania
- Harvard University
